Drug Profile
AF 130
Alternative Names: AF-130Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Roche
- Developer Merck & Co
- Class Analgesics; Antihypertensives; Heart failure therapies; Small molecules
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertension; Migraine
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Hypertension in United Kingdom (PO)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Migraine in United Kingdom (PO)
- 18 May 2016 Afferent Pharmaceuticals completes a phase I trial in healthy volunteers in USA (NCT02652936)